510(k) device
Tandem Mobi insulin pump with interoperable technology
Tandem Diabetes Care, Inc. · Alternate Controller Enabled Insulin Infusion Pump (QFG, Class II) · First FDA decision Jul 10, 2023, newest Nov 6, 2025Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
510(k) pathway
Device trials
5
Naming "Tandem Mobi"
MAUDE reports
87,082
Brand "Tandem Mobi", since 2015
PubMed studies
5
Mentioning "Tandem Mobi"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Tandem Mobi insulin pump with interoperable technology
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
K253074 · Decided Nov 6, 2025 · 44 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
K241078 · Decided Jul 26, 2024 · 98 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
K240309 · Decided Mar 21, 2024 · 48 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Insulin Infusion PumpNational analysisReview closedCAG-00041NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Tandem Mobi", any status and sponsor, newest update first.
- Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by PredictionActive, not recruiting
Sue BrownAcademic, hospital or other
NCT07507708 · 20 participants (planned) · Start May 14, 2026 · Primary completion Mar 31, 2027
Device: Automated Insulin Delivery (AID); AIDANET + Fully Closed Loop (FCL) and 1 more · For: Type 1 Diabetes (T1D)
Sites: Charlottesville, Virginia
Tandem Diabetes Care, Inc.Public (TNDM)
NCT06717451 · 144 participants · Start Jan 30, 2025 · Primary completion Aug 10, 2026
Device: Control-IQ Technology v1.5 · For: Type 1 Diabetes
Sites: San Diego, California
Tandem Diabetes Care, Inc.Public (TNDM)
NCT07325461 · 20 participants · Start Feb 18, 2026 · Primary completion Jun 24, 2026
Device: SteadiSet Infusion Set · For: Diabetes Mellitus, Type 1
Sites: Stanford, California
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Tandem Mobi", and for the whole product code for context.
This brand
87,082 reports: 73,859 malfunction, 13,192 injury, 9 death
Whole product code QFG
1,370,384 reports: 1,216,047 malfunction, 153,806 injury, 383 death
Newest reports for this brand
3013756811-2026-197913 · Received Oct 30, 2026 · Event dated Jul 18, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3013756811-2026-197905 · Received Oct 30, 2026 · Event dated Oct 3, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3013756811-2026-197903 · Received Oct 30, 2026 · Event dated Oct 9, 2026
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Device problem as coded: Obstruction of Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0316-2027 · Started Sep 23, 2026 · Posted by FDA Oct 30, 2026
Reason given: Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that increased friction within the drive module can reduce available motor power and, under certain...
Cause as FDA categorized it: Process change control · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Z-0427-2026 · Started Oct 6, 2025 · Posted by FDA Nov 5, 2025
Reason given: Insulin pump includes a vibration motor that gives tactile feedback for any alerts, alarms, or malfunctions. Pump may exhibit false vibration motor failure due to a software issue causing Malfunction 12: "Pump cannot operate, the mobile app can no longer receive data from the pump. Insulin delivery and any active CGM...
Cause as FDA categorized it: Software design · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
Z-0232-2026 · Started Aug 5, 2025 · Posted by FDA Oct 23, 2025
Reason given: A software defect in versions 7.9.0.1 and 7.10.1 of the pump software for Tandem t:slim X2 and version 7.9.0.1 of the Tandem Mobi pump with Control-IQ+ technology that are paired with a G7 sensor may result in an unexpected automatic insulin correction bolus (autobolus ) which could result in hypoglycemia.
Cause as FDA categorized it: Software change control · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Tandem Mobi"[tiab]. The summary above synthesizes these.
- First Use of Control-IQ+ Technology in Newly Indicated Populations.
Assadi KZ, D'Souza EW, Pinsker JE, et al. · Diabetes Technol Ther · 2026
- Glycemic and Patient-Reported Outcomes for Users of a New, Compact Automated Insulin Delivery System: A First Report.
Akturk HK, Karakus KE, D'Souza E, et al. · J Diabetes Sci Technol · 2025Letter
- An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy.
Sawyer A, Forlenza GP, Wadwa RP · Expert Rev Med Devices · 2025Review
- Real-world outcomes using the Tandem Mobi insulin pump with Control-IQ+ technology and Dexcom G7.
D'Souza EW, Castle JR, Assadi KZ, et al. · Diabet Med · 2026
- Diabetes Distress in Caregivers of Young Children With Type 1 Diabetes Mellitus.
Georges ED, Parimi N, Dimentstein K, et al. · J Diabetes Sci Technol · 2026
Other devices of this type
Also filed under product code QFG.
- t:slim X2 insulin pump with interoperable technologyTandem Diabetes Care, Inc. · De Novo 2025
- iLet ACE PumpBeta Bionics, Inc. · 510(k) 2026
- DEKA ACE Pump SystemDeka Research and Development · 510(k) 2024
- Mint ACE PumpBeta Bionics, Inc. · 510(k) 2026
- MiniMed 780G Insulin Pump (MMT-1884)Medtronic Minimed, Inc. · 510(k) 2026
- Omnipod 5 ACE PumpInsulet Corporation · 510(k) 2023
- twiist Automated Insulin Delivery (AID) SystemDeka Research and Development · 510(k) 2026
- MiniMed Flex pumpMedtronic Minimed, Inc. · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.